LOKI THERAPEUTICS, INC
Clinical testing of Listeria-TT and Gemcitabine in a Phase I clinical trial with PDAC patients
Clinical testing of Listeria-TT and Gemcitabine in a Phase I clinical trial with PDAC patients is a funding opportunity from LOKI THERAPEUTICS, INC, up to 294962, closing December 31, 2026.
Dec 31, 2026
(153d left)Overview
ABSTRACT The overall objective of this STTR Fast-Track project is to prepare and perform a Phase I clinical trial in metastatic unresectable pancreatic ductal cancer adenocarcinoma (PDAC) patients of a new immunotherapeutic approach based on tetanus recall antigens delivered by bacteria (Listeria-Tetanus Toxoid) with…